Innate Pharma reports preliminary antitumor activity for IPH4502 in Phase 1 trial
IPHA•Innate Pharma reported preliminary antitumor activity for its experimental IPH4502 antibody-drug conjugate across several advanced solid tumor types, including urothelial cancer previously treated with enfortumab vedotin. Stomatitis was the only reported dose-limiting toxicity; the company expects to begin dose optimization in previously treated urothelial cancer in the first half of 2027.
1. Initial Phase 1 findings
Innate Pharma presented initial Phase 1 results for IPH4502 in advanced solid tumors at ENA 2026. The experimental Nectin-4-targeting antibody-drug conjugate showed preliminary antitumor activity across several tumor types, including urothelial cancer previously treated with enfortumab vedotin.
2. Safety and next stage
The company reported low overall blood-related toxicity, with stomatitis the only dose-limiting toxicity. Dose optimization will focus on previously treated urothelial cancer, with the first patient expected in the first half of 2027; the next stage will test split dosing with mandatory stomatitis prevention to guide selection of a Phase 2 regimen.




